Raloxifene vs Clomiphene — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Estrogen Agonist/Antagonist

Raloxifene

Brand: Evista

First FDA approval: 1998-01-06

Estrogen Agonist/Antagonist

Clomiphene

Brand: CLOMID

First FDA approval: 2022-09-09

Lowest NADACAcquisition cost floor across all NDCs

$0.248Per unit

$6.64Per unit

Average NADACAcross all dosage forms and strengths

$0.483Up to $6.34

$7.40Up to $11.16

Generic manufacturersActive ANDA holders — FDA Orange Book

88 total ANDAs filed

66 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$48.7MFull year

$1.4MFull year

Part D claims (CY24)Total fills, all strengths

1.1M322K beneficiaries

7K2K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$46Per claim, all NDCs

$218Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes8 manufacturers

Yes6 manufacturers